Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 55.39 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eidos Therapeutics Inc | EIDX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.18 | -0.32% | 55.39 | 56.06 | 55.02 | 56.06 | 55.57 | 16:30:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 50.00 | 57.91 | 7.91 | 13.66% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 919 | 43,652 | $ 55.57 | $ 2,425,769 | 156,232 | 11.15 - 66.5587 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:30:50 | priorref | 591 | $ 55.39 | USD |
Eidos Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 2.08B | 37.50M | $ -40.73M | -1.95 | - | 37.03M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Eidos Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EIDX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 57.90 | 58.20 | 52.67 | 54.79 | 94,876 | -2.51 | -4.34% |
| 1 Month | 61.05 | 61.93 | 52.67 | 57.89 | 108,530 | -5.66 | -9.27% |
| 3 Months | 39.37 | 66.5587 | 38.0418 | 54.92 | 169,715 | 16.02 | 40.69% |
| 6 Months | 40.72 | 66.5587 | 28.00 | 46.05 | 170,838 | 14.67 | 36.03% |
| 1 Year | 12.84 | 66.5587 | 11.15 | 36.70 | 158,295 | 42.55 | 331.39% |
| 3 Years | 20.00 | 66.5587 | 8.89 | 28.36 | 167,433 | 35.39 | 176.95% |
| 5 Years | 20.00 | 66.5587 | 8.89 | 28.36 | 167,433 | 35.39 | 176.95% |
Eidos Therapeutics Description
| Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. |
